

## Donated medicines and health products by disease and donor commitment (as of February 2025)

Disease	Manufacturer	Product name	MoU period	Current donation commitment
Donations managed by WHO				
Chagas disease	Bayer AG (Germany)	Nifurtimox (120 mg tablets)	2007–2025	<ul style="list-style-type: none"> <li>Up to a total of 12 500 000 tablets for the treatment of Chagas disease</li> </ul>
	Chemo Group (Mundo Sano)	Benznidazole (100 mg tablet; 12.5 mg tablet)	2020–2023	<ul style="list-style-type: none"> <li>3000 tablets (12.5mg)/105 000 tablets (100 mg)</li> </ul>
Foodborne trematode infections (fascioliasis and paragonimiasis)	Novartis (Switzerland)	Triclabendazole (250 mg tablets)	2016–2025	<ul style="list-style-type: none"> <li>Up to 600 000 tablets for the treatment of fascioliasis and paragonimiasis</li> </ul>
Foodborne trematodiasis (clonorchiasis and opisthorchiasis)	Bayer AG (Germany)	Praziquantel (600 mg tablets)	2020–2024	<ul style="list-style-type: none"> <li>Within the limits of the donation of praziquantel for taeniasis/cysticercosis</li> </ul>
Human African trypanosomiasis (HAT)	Bayer AG (Germany)	Nifurtimox (120 mg tablets)	2009–2026	<ul style="list-style-type: none"> <li>Up to 150 000 tablets for 5 years, adjustable to needs to treat HAT</li> </ul>
		Suramin (1 g in vial)	2002–2026	<ul style="list-style-type: none"> <li>Up to 10 000 vials for 5 years, adjustable to needs to treat HAT</li> </ul>
	Sanofi (France)	<ul style="list-style-type: none"> <li>Eflornithine (200 mg per mL in 100 mL bottle);</li> <li>Melarsoprol (3.6% in 5 mL ampoule solution (180 mg of active compound);</li> <li>Pentamidine (200 mg powder for injection)</li> </ul>	2001–2026	<ul style="list-style-type: none"> <li>Unlimited quantity for the treatment of HAT</li> </ul>
		Fexinidazole (600 mg tablets)	2019–2026	
	Cytiva (Sweden)	Diagnostics of HAT. DE52 cellulose (10 kg pack size) and cytopore 2 (1 kg pack size)	2022-2024	<ul style="list-style-type: none"> <li>230 kg of DE52 cellulose, and 9 kg of cytopore 2 enough to cover the need until 2025</li> </ul>
Leprosy	Novartis (Switzerland)	Clofazimine (100 mg capsule)	2000–2025	<ul style="list-style-type: none"> <li>Up to 1 650 000 capsules for the treatment of severe erythema nodosum leprosum reactions</li> </ul>
		Clofazimine		

Disease	Manufacturer	Product name	MoU period	Current donation commitment
		(50 mg capsule)		<ul style="list-style-type: none"> <li>Up to 2 478 000 blisters annually for the treatment of leprosy and its complications</li> </ul>
		MDT* MB adult and child		
		MDT PB adult and child		
		Rifampicin (150 mg, 300 mg, syrup)	2024–2025	<ul style="list-style-type: none"> <li>Funding procurement of single-dose rifampicin for leprosy chemoprophylaxis (SDR-LEP) for contacts with active leprosy patients</li> </ul>
Lymphatic filariasis (LF)	Eisai (Japan)	Diethylcarbamazine citrate (100 mg tablets)	Since 2012 until elimination of LF	<ul style="list-style-type: none"> <li>Up to 2.2 billion tablets committed for first 7-year period for use in the preventive chemotherapy of LF</li> <li>Extended in 2017 until elimination is achieved</li> <li>Current MoU runs until 2025</li> </ul>
	GlaxoSmithKline (GSK) (United Kingdom)	Albendazole (400 mg tablets)	Since 1997 until elimination of LF	<ul style="list-style-type: none"> <li>Up to 600 million tablets annually for use in the preventive chemotherapy of LF</li> </ul>
Schistosomiasis	Merck KGaA (Germany)	Praziquantel (600 mg tablets)	Since 2007 for an unlimited period	<ul style="list-style-type: none"> <li>Up to 200 million tablets annually for the treatment of schistosomiasis in school-aged children (notably in Africa)</li> <li>Since 2017, donation scaled up to 250 million tablets annually for the treatment of schistosomiasis in school-aged children and adults (in specific epidemiological contexts)</li> </ul>
Soil-transmitted helminthiasis (STH)	GlaxoSmithKline (GSK) (United Kingdom)	Albendazole (400 mg tablets)	2012–2025	<ul style="list-style-type: none"> <li>Up to 200 million tablets annually for use in the preventive chemotherapy of STH</li> </ul>
	Janssen Pharmaceuticals, Inc. (United States)	Mebendazole (500 mg tablets)	Since 2012; current MoU runs until 2025	<ul style="list-style-type: none"> <li>Up to 200 million tablets annually for the treatment of STH in school-age children and women of reproductive age</li> </ul>
Visceral leishmaniasis (VL)	Gilead Sciences, Inc. (United States)	Liposomal amphotericin B (lyophilized 50 mg formulation in vials) (AmBisome®)	2012–2016	<ul style="list-style-type: none"> <li>Up to 445 000 vials for the treatment of VL in South-East Asia and East Africa</li> </ul>
			2016–2021	<ul style="list-style-type: none"> <li>Up to 380,400 vials for the treatment of VL in South-East Asia and East Africa</li> </ul>
			2022–2025	<ul style="list-style-type: none"> <li>Up to 304 700 vials for the treatment of VL in South-East Asia and East Africa</li> </ul>
Yaws	EMS SA Pharma (Brazil)	Azithromycin (500 mg tablets)	2019–2024	<ul style="list-style-type: none"> <li>153 million tablets to support the global eradication of yaws</li> </ul>

Disease	Manufacturer	Product name	MoU period	Current donation commitment
			2025–2030	<ul style="list-style-type: none"><li>143 million tablets to support the global eradication of yaws.</li></ul>
Taeniasis and cysticercosis	Bayer AG (Germany)	Niclosamide (400 mg tablets)	2020–2024	<ul style="list-style-type: none"><li>Up to a total of 2 800 000 tablets for the treatment of taeniasis</li></ul>
		Praziquantel (600 mg tablets)		<ul style="list-style-type: none"><li>Up to a total of 1 339 000 tablets for the treatment of taeniasis</li></ul>
Cystic echinococcosis	GlaxoSmithKline (GSK) (United Kingdom)	Albendazole (400 mg tablets)	2022–2025	<ul style="list-style-type: none"><li>Up to 5 million tablets within the limit of the overall donation of albendazole from GSK</li></ul>
Donations managed outside WHO				
Onchocerciasis	Merck, Sharpe and Dohme (MSD) (United States)	Ivermectin (3 mg tablets)	Since 1987 until elimination of onchocerciasis	<ul style="list-style-type: none"><li>Unlimited supply for the treatment of onchocerciasis</li></ul>
Lymphatic filariasis (LF)			Since 1997 until elimination of LF	<ul style="list-style-type: none"><li>Unlimited supply for the treatment of LF</li></ul>
			2018–2025 for IDA strategy	<ul style="list-style-type: none"><li>Up to 250 million tablets for use in WHO-recommended triple-therapy (IDA) MDA regimens to eliminate LF in countries not co-endemic for onchocerciasis</li></ul>
Trachoma	Pfizer Inc. (United States)	Azithromycin (250 mg tablets or 1200 mg in 30 mL (200 mg/5 mL) powder for oral suspension)	1998–2025	<ul style="list-style-type: none"><li>Unlimited quantity for the elimination of trachoma as a public health problem</li></ul>

MB: multibacillary; MoU: memorandum of understanding; PB: paucibacillary.

\*MDT: multidrug therapy (rifampicin (150 mg and 300 mg tablets), clofazimine (300 mg and 50 mg tablets), dapsone (100 mg tablets)) in blister packs depending on age and type of leprosy; loose clofazimine in capsules.